Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure

Serge Masson, Tarcisio Vago, Gabriella Baldi, Monica Salio, Noeleen De Angelis, Enrico Nicolis, Aldo P. Maggioni, Roberto Latini, Guido Norbiato, Maurizio Bevilacqua

Research output: Contribution to journalArticle

Abstract

It is not clear whether brain natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) is superior as a diagnostic and prognostic indicator in cardiac diseases. Here, we compare the clinical correlations of both peptides in a population of 92 ambulatory patients with heart failure, using a well-established immunoradiometric assay (IRMA) for BNP and an automated electrochemiluminescence immunoassay for NT-proBNP. The analytical correlation between the two peptides was satisfactory over a wide range of concentrations (1-686 pM for BNP) with the equation: NT-proBNP = 3.48 x BNP -19 and a correlation coefficient r2=0.94. In addition, the concentration of both peptides increased in a similar fashion according to the severity of the disease New York Heart Association (NYHA) functional class, left ventricular ejection fraction, etiology) and age; for instance, the ratios between median levels measured in NYHA class III vs. class II patients were comparable for BNP (383 vs. 16 pM, ratio 24) and NT-proBNP (1306 vs. 57 pM, ratio 23). We conclude that N-terminal proBNP, as assayed in the present study, correlates equally to BNP with clinical variables in patients with heart failure.

Original languageEnglish
Pages (from-to)761-763
Number of pages3
JournalClinical Chemistry and Laboratory Medicine
Volume40
Issue number8
DOIs
Publication statusPublished - 2002

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Peptides
Immunoradiometric Assay
Immunoassay
Stroke Volume
Heart Diseases
Assays
pro-brain natriuretic peptide (1-76)
Population

Keywords

  • Brain natriuretic peptide
  • Heart failure
  • N-terminal pro-brain natriuretic peptide

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. / Masson, Serge; Vago, Tarcisio; Baldi, Gabriella; Salio, Monica; De Angelis, Noeleen; Nicolis, Enrico; Maggioni, Aldo P.; Latini, Roberto; Norbiato, Guido; Bevilacqua, Maurizio.

In: Clinical Chemistry and Laboratory Medicine, Vol. 40, No. 8, 2002, p. 761-763.

Research output: Contribution to journalArticle

Masson, Serge ; Vago, Tarcisio ; Baldi, Gabriella ; Salio, Monica ; De Angelis, Noeleen ; Nicolis, Enrico ; Maggioni, Aldo P. ; Latini, Roberto ; Norbiato, Guido ; Bevilacqua, Maurizio. / Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. In: Clinical Chemistry and Laboratory Medicine. 2002 ; Vol. 40, No. 8. pp. 761-763.
@article{e206c674aad04785972143711d193a4b,
title = "Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure",
abstract = "It is not clear whether brain natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) is superior as a diagnostic and prognostic indicator in cardiac diseases. Here, we compare the clinical correlations of both peptides in a population of 92 ambulatory patients with heart failure, using a well-established immunoradiometric assay (IRMA) for BNP and an automated electrochemiluminescence immunoassay for NT-proBNP. The analytical correlation between the two peptides was satisfactory over a wide range of concentrations (1-686 pM for BNP) with the equation: NT-proBNP = 3.48 x BNP -19 and a correlation coefficient r2=0.94. In addition, the concentration of both peptides increased in a similar fashion according to the severity of the disease New York Heart Association (NYHA) functional class, left ventricular ejection fraction, etiology) and age; for instance, the ratios between median levels measured in NYHA class III vs. class II patients were comparable for BNP (383 vs. 16 pM, ratio 24) and NT-proBNP (1306 vs. 57 pM, ratio 23). We conclude that N-terminal proBNP, as assayed in the present study, correlates equally to BNP with clinical variables in patients with heart failure.",
keywords = "Brain natriuretic peptide, Heart failure, N-terminal pro-brain natriuretic peptide",
author = "Serge Masson and Tarcisio Vago and Gabriella Baldi and Monica Salio and {De Angelis}, Noeleen and Enrico Nicolis and Maggioni, {Aldo P.} and Roberto Latini and Guido Norbiato and Maurizio Bevilacqua",
year = "2002",
doi = "10.1515/CCLM.2002.130",
language = "English",
volume = "40",
pages = "761--763",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",
number = "8",

}

TY - JOUR

T1 - Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure

AU - Masson, Serge

AU - Vago, Tarcisio

AU - Baldi, Gabriella

AU - Salio, Monica

AU - De Angelis, Noeleen

AU - Nicolis, Enrico

AU - Maggioni, Aldo P.

AU - Latini, Roberto

AU - Norbiato, Guido

AU - Bevilacqua, Maurizio

PY - 2002

Y1 - 2002

N2 - It is not clear whether brain natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) is superior as a diagnostic and prognostic indicator in cardiac diseases. Here, we compare the clinical correlations of both peptides in a population of 92 ambulatory patients with heart failure, using a well-established immunoradiometric assay (IRMA) for BNP and an automated electrochemiluminescence immunoassay for NT-proBNP. The analytical correlation between the two peptides was satisfactory over a wide range of concentrations (1-686 pM for BNP) with the equation: NT-proBNP = 3.48 x BNP -19 and a correlation coefficient r2=0.94. In addition, the concentration of both peptides increased in a similar fashion according to the severity of the disease New York Heart Association (NYHA) functional class, left ventricular ejection fraction, etiology) and age; for instance, the ratios between median levels measured in NYHA class III vs. class II patients were comparable for BNP (383 vs. 16 pM, ratio 24) and NT-proBNP (1306 vs. 57 pM, ratio 23). We conclude that N-terminal proBNP, as assayed in the present study, correlates equally to BNP with clinical variables in patients with heart failure.

AB - It is not clear whether brain natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) is superior as a diagnostic and prognostic indicator in cardiac diseases. Here, we compare the clinical correlations of both peptides in a population of 92 ambulatory patients with heart failure, using a well-established immunoradiometric assay (IRMA) for BNP and an automated electrochemiluminescence immunoassay for NT-proBNP. The analytical correlation between the two peptides was satisfactory over a wide range of concentrations (1-686 pM for BNP) with the equation: NT-proBNP = 3.48 x BNP -19 and a correlation coefficient r2=0.94. In addition, the concentration of both peptides increased in a similar fashion according to the severity of the disease New York Heart Association (NYHA) functional class, left ventricular ejection fraction, etiology) and age; for instance, the ratios between median levels measured in NYHA class III vs. class II patients were comparable for BNP (383 vs. 16 pM, ratio 24) and NT-proBNP (1306 vs. 57 pM, ratio 23). We conclude that N-terminal proBNP, as assayed in the present study, correlates equally to BNP with clinical variables in patients with heart failure.

KW - Brain natriuretic peptide

KW - Heart failure

KW - N-terminal pro-brain natriuretic peptide

UR - http://www.scopus.com/inward/record.url?scp=18544389492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18544389492&partnerID=8YFLogxK

U2 - 10.1515/CCLM.2002.130

DO - 10.1515/CCLM.2002.130

M3 - Article

C2 - 12392300

AN - SCOPUS:18544389492

VL - 40

SP - 761

EP - 763

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 8

ER -